基本數據
| CIK | 846475 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zynex, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| March 26, 2026 |
As filed with the Securities and Exchange Commission on March 26, 2026 As filed with the Securities and Exchange Commission on March 26, 2026 Registration No. |
|
| March 26, 2026 |
SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION ZYNEX, INC. Exhibit 3.3 SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ZYNEX, INC. The undersigned Thomas Sandgaard, Steven Dyson, hereby certifies that: 1.He is the duly elected and acting PresidentChief Executive Officer of Zynex, Inc., a Nevada corporation. 2.The Articles of Incorporation of this corporation were originally filed with the Secretary of State of Nevada on December 31, 2001. The cor |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2026 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38804 Zynex, Inc. (Exact name of registrant as specified in is charter) |
|
| March 26, 2026 |
SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION ZYNEX, INC. Exhibit 3.1 SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ZYNEX, INC. The undersigned, Steven Dyson, hereby certifies that: 1.He is the duly elected and acting Chief Executive Officer of Zynex, Inc., a Nevada corporation. 2.The Articles of Incorporation of this corporation were originally filed with the Secretary of State of Nevada on December 31, 2001. The corporation’s Articles of Inc |
|
| March 26, 2026 |
Exhibit 3.4 SECOND AMENDED & RESTATED BYLAWS OF ZYNEX, INC. a Nevada corporation (October 3March 26, 20082026) ARTICLE I. OFFICES Section 1.Registered Office. The registered office shall be maintained at such place as the Board of Directors shall determine from time to time. Section 2.Other Offices. The corporation may also have offices at such other places both within and without the State of Nev |
|
| March 26, 2026 |
As filed with the Securities and Exchange Commission on March 26, 2026 As filed with the Securities and Exchange Commission on March 26, 2026 Registration No. |
|
| March 26, 2026 |
SECOND AMENDED & RESTATED BYLAWS ZYNEX, INC. a Nevada corporation (March 26, 2026) ARTICLE I. Exhibit 3.2 SECOND AMENDED & RESTATED BYLAWS OF ZYNEX, INC. a Nevada corporation (March 26, 2026) ARTICLE I. OFFICES Section 1.Registered Office. The registered office shall be maintained at such place as the Board of Directors shall determine from time to time. Section 2.Other Offices. The corporation may also have offices at such other places both within and without the State of Nevada as the Bo |
|
| March 20, 2026 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION Exhibit 2.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In re: ZYNEX, INC., et al., Debtors.1 § § § § § § § Chapter 11 Case No. 25-90810 (ARP) (Jointly Administered) THIRD AMENDED COMBINED DISCLOSURE STATEMENT AND JOINT PLAN OF REORGANIZATION OF ZYNEX, INC. AND ITS AFFILIATED DEBTORS PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE REED SMITH LLP Omar J. |
|
| March 20, 2026 |
UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION Exhibit 2.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In re: ZYNEX, INC., et al.,1 Debtors. Chapter 11 Case No. 25-90810 (ARP) (Jointly Administered) Ref. Docket Nos. 263, 304, 329, 330, 331 FINDINGS OF FACT, CONCLUSIONS OF LAW AND ORDER (I) APPROVING THE ADEQUACY OF THE DEBTORS’ DISCLOSURE STATEMENT AND (II) CONFIRMING THE THIRD AMENDED COMBINED DISCLOSURE STATEME |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 19, 2026 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38804 (Commission File Number) 90-0275169 ( |
|
| March 13, 2026 |
As filed with the Securities and Exchange Commission on March 13, 2026 As filed with the Securities and Exchange Commission on March 13, 2026 Registration No. |
|
| March 13, 2026 |
March 13, 2026 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 18, 2026 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38804 (Commission File Number) 90-027516 |
|
| February 18, 2026 |
Zynex Poised for New Future with Resolution of Federal Investigation Exhibit 99.1 Zynex Poised for New Future with Resolution of Federal Investigation ENGLEWOOD, Colo., Feb. 17, 2026 — Zynex, Inc., today announced that it has resolved the federal government’s investigation into business practices designed and implemented by the company’s former executives. Under the non-prosecution agreement (NPA) signed today, the United States Attorney’s Office for the District o |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 17, 2026 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38804 (Commission File Number) 90-027516 |
|
| February 18, 2026 |
ATTACHMENT A STATEMENT OF FACTS Exhibit 10.1 U.S. Department of Justice United States Attorney’s Office District of Rhode Island One Financial Plaza, 17th Floor (401) 709-5000 Providence, Rhode Island 02903 FAX (401) 709-5001 February 17, 2026 Jeffrey Layne Benjamin Koplin Reed Smith Austin, TX [email protected] [email protected] Re:Zynex Non-Prosecution Agreement Dear Counsel: The United States Attorney’s Office for the |
|
| February 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2026 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38804 (Commission File Number) 90-0275169 |
|
| January 23, 2026 |
New Zynex Leadership Responds to Indictment of Former Executives Exhibit 99.1 New Zynex Leadership Responds to Indictment of Former Executives ENGLEWOOD, Colo., Jan. 22, 2026 — Zynex, Inc. (ZYXIQ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today issued the following statement regarding the federal indictments of two former executives. “Zynex, Inc. is |
|
| January 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 22, 2026 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38804 (Commission File Number) 90-0275169 |
|
| January 23, 2026 |
Delisting Determination, The Nasdaq Stock Market, LLC, January 13, 2026 Zynex, Inc. |
|
| January 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 14, 2026 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 15, 2026 |
FIRST AMENDMENT TO SENIOR SECURED DEBTOR-IN-POSSESSION CREDIT AGREEMENT Exhibit 10.1 EXECUTION VERSION FIRST AMENDMENT TO SENIOR SECURED DEBTOR-IN-POSSESSION CREDIT AGREEMENT FIRST AMENDMENT TO SENIOR SECURED DEBTOR-IN-POSSESSION CREDIT AGREEMENT, dated as of January 14, 2026 (this “First Amendment”), among ZYNEX, INC., a Nevada corporation (“Borrower”), the Guarantors party hereto, the Lenders party hereto and WILMINGTON SAVINGS FUND SOCIETY, FSB, in its capacity as |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2025 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 18, 2025 |
Exhibit 10.1 EXECUTION VERSION $22,300,000 SENIOR SECURED DEBTOR-IN-POSSESSION CREDIT AGREEMENT dated as of December 17, 2025 among ZYNEX, INC., as Borrower, and THE GUARANTORS PARTY HERETO, as Guarantors, and THE LENDERS PARTY HERETO and WILMINGTON SAVINGS FUND SOCIETY, FSB, as Administrative Agent and Collateral Agent, TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.01 Defined Terms 1 Sectio |
|
| December 16, 2025 |
Exhibit 99.2 NASDAQ: ZYXI Discussion Materials November 13, 2025 NASDAQ: ZYXI Disclaimer The purpose of this presentation (the “Presentation”) is to introduce the reader to Zynex, Inc. (“Zynex” or the “Company”) and Province, LLC (“Province”). This Presentation is being made available only to parties who have signed and returned a Confidentiality Agreement. Recipients agree to use and maintain the |
|
| December 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 15, 2025 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| December 16, 2025 |
RESTRUCTURING SUPPORT AGREEMENT Exhibit 10.1 THIS RESTRUCTURING SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE. Nothing contained in thIS RESTRUCTURING SUPPORT AGREEME |
|
| December 16, 2025 |
9655 Maroon Circle, Englewood, CO 80112 | Zynex.com Exhibit 99.1 Zynex Financial Restructuring Puts Company on Path to Long-Term Success ENGLEWOOD, Colo., Dec. 16, 2025 — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation today announced it has voluntarily entered into a Chapter 11 court-supervised financial restructurin |
|
| November 17, 2025 |
Separation Agreement, dated October 27, 2025, between Zynex Medical, Inc. and Anna Lucsok Exhibit 10.4 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (“Agreement”) is entered on October 27, 2025 (“Effective Date”) by and between Anna Lucsok (“Executive” “you,” or “your”) and Zynex Medical, Inc. (“Company”) (collectively, “Parties”). A. WHEREAS, the Parties are parties to an Employment Agreement effective January 27, 2021 attached to this Agre |
|
| November 17, 2025 |
Employment Agreement, dated August 18, 2025, between Zynex, Inc. and John T. Bibb Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is effective as of August 18, 2025 (“Effective Date”), between Zynex, Inc., a Nevada corporation headquartered at 9655 Maroon Circle, Englewood, Colorado 80112, USA (“Company”), and John Bibb (“Executive”) (collectively, “Parties”). A. Company is a duly organized Nevada corporation, with its principal place of business withi |
|
| November 17, 2025 |
Employment Agreement, dated August 18, 2025, between Zynex, Inc. and Vikram Singh Bajaj Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is effective as of August 18, 2025 (“Effective Date”), between Zynex, Inc., a Nevada corporation headquartered at 9655 Maroon Circle, Englewood, Colorado 80112, USA (“Company”), and Vikram Bajaj (“Executive”) (collectively, “Parties”). A. Company is a duly organized Nevada corporation, with its principal place of business wi |
|
| November 17, 2025 |
Independent Contractor Agreement, dated September 1, 2025, between Zynex, Inc. and Daniel Moorhead Exhibit 10.3 INDEPENDENT CONTRACTOR AGREEMENT This INDEPENDENT CONTRACTOR AGREEMENT (“Agreement”) is being entered into on September 1, 2025 (“Effective Date”) by and between Zynex Medical, Inc., a Colorado corporation located at 9655 Maroon Circle, Englewood, CO 80112 (“Zynex”) and Daniel Moorhead, an individual located at 6832 Balsamroot Road, Larkspur, CO 80118 (“Contractor”) (collectively, “Pa |
|
| November 17, 2025 |
Zynex Reports Third Quarter 2025 Financial Results Exhibit 99.1 Zynex Reports Third Quarter 2025 Financial Results ENGLEWOOD, Colo., November 17, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, and rehabilitation, today reported its financial and operational results for the third quarter ended September 30, 2025. Management Com |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-38804 CUSIP NUMBER: 98986M 103 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ |
|
| October 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I |
|
| October 14, 2025 |
Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair Exhibit 99.1 Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair ENGLEWOOD, Colo., October 14, 2025 /PRNewswire/ - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise t |
|
| October 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I |
|
| September 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| August 20, 2025 |
Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles Exhibit 99.1 Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles ENGLEWOOD, Colo., August 18, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, St |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I |
|
| July 31, 2025 |
Zynex Reports Second Quarter 2025 Financial Results Exhibit 99.1 Zynex Reports Second Quarter 2025 Financial Results ENGLEWOOD, Colo., July 31, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. M |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| July 31, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 30, 2025 |
July 30, 2025 Daniel Moorhead Chief Financial Officer ZYNEX INC 9655 Maroon Circle Englewood, CO 80112 Re: ZYNEX INC 10-K/A filed July 24, 2025 File No. |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| July 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| July 11, 2025 |
July 11, 2025 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N. |
|
| July 2, 2025 |
Tricare Temporary Payment Suspension Update Exhibit 99.1 Tricare Temporary Payment Suspension Update ENGLEWOOD, Colo., July 2, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company received an update from Tricare that the temporary payment suspension will cont |
|
| July 2, 2025 |
Form of Indemnification Agreement Exhibit 10.2 FORM OF ZYNEX, INC. INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (“Agreement”), dated as of [DATE] (“Effective Date”), is by and between Zynex, Inc., a Nevada corporation (“Company”) and [NAME OF DIRECTOR/OFFICER] (“Indemnitee”) (collectively, “Parties”). A. Indemnitee is [a director/an officer] of Company/Company expects Indemnitee to join Company as [a director/an office |
|
| July 2, 2025 |
Zynex Announces Steven Dyson as New CEO Exhibit 99.1 Zynex Announces Steven Dyson as New CEO Englewood, CO – June 30, 2025 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. His employment will begin on August 18, 2025. Thomas Sandgaard, F |
|
| July 2, 2025 |
Employment Agreement, dated May 23, 2025, between Zynex, Inc. and Steven Dyson Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is effective as of May 23, 2025 (“Effective Date”), between Zynex, Inc., a Nevada corporation headquartered at 9655 Maroon Circle, Englewood, Colorado 80112, USA, (“Company”), and Steven Dyson, PhD (“Executive”) (collectively, “Parties”). A. Company is a duly organized Nevada corporation, with its principal place of business |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| July 2, 2025 |
July 2, 2025 Daniel Moorhead Chief Financial Officer ZYNEX INC 9655 Maroon Circle Englewood, CO 80112 Re: ZYNEX INC Correspondence filed June 5, 2025 File No. |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| June 5, 2025 |
June 5, 2025 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N. |
|
| May 21, 2025 |
May 21, 2025 Daniel Moorhead Chief Financial Officer ZYNEX INC 9655 Maroon Circle Englewood, CO 80112 Re: ZYNEX INC Form 10-K filed March 11, 2025 File No. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| May 14, 2025 |
Zynex Submits FDA Application for Its NiCO Laser Pulse Oximeter Exhibit 99.1 Zynex Submits FDA Application for Its NiCO Laser Pulse Oximeter ENGLEWOOD, Colo., May 12, 2025 /PRNewswire/ - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has submitted a 510(k) application to the U.S. Food and |
|
| April 29, 2025 |
Zynex Reports First Quarter 2025 Financial Results Exhibit 99.1 Zynex Reports First Quarter 2025 Financial Results ENGLEWOOD, Colo., April 29, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. M |
|
| April 29, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| April 25, 2025 |
Table of Contents Registration No. 333-[ ] SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada 90-0275169 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9655 Maroon Circle Englewood, CO 80112 (800) 495- |
|
| April 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zynex, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934s Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| March 27, 2025 |
Letter from Marcum LLP to the Securities and Exchange Commission dated March 27, 2025. EX-16.1 2 zyxi-20250327xex16d1.htm EX-16.1 Exhibit 16.1 March 27, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Zynex, Inc. under Item 4.01 of its Form 8-K dated March 27, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| March 11, 2025 |
Insider Trading Policy, as initially adopted on February 26, 2004 and as amended, from time to time. Exhibit 19.1 ZYNEX INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) provides guidelines to all employees, officers, and affiliates of Zynex, Inc., and its subsidiaries (the “Company”), as well as members of the Company’s Board of Directors (the “Directors”), with respect to transactions in the Company’s securities and codifies the Company’s standards on trading and enabling, or ca |
|
| March 11, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 |
|
| March 11, 2025 |
Zynex Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Zynex Reports Fourth Quarter and Full Year 2024 Financial Results ENGLEWOOD, Colo., March 11, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and ful |
|
| March 11, 2025 |
Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. Name Jurisdiction Zynex Medical, Inc. Colorado Zynex Monitoring Solutions, Inc. Colorado Zynex NeuroDiagnostics, Inc. Colorado Kestrel Labs, Inc. Colorado |
|
| March 11, 2025 |
Exhibit 10.4 LEASE AGREEMENT BY AND BETWEEN TWO MAROON CIRCLE INVESTORS, LLC, a Delaware limited liability company AS LANDLORD AND ZYNEX, INC., a Nevada corporation AS TENANT DATED FEBRUARY , 2023 TABLE OF CONTENTS 1. DEMISE 2 2. PREMISES 2 3. TERM 4 4. RENT 4 5. UTILITIES AND SERVICES 15 6. LATE CHARGE 19 7. SECURITY DEPOSIT 20 8. POSSESSION; COMPLETION OF THE LANDLORD WORK 20 9. USE OF PREMISES; |
|
| October 24, 2024 |
Zynex Reports Third Quarter 2024 Financial Results Exhibit 99.1 Zynex Reports Third Quarter 2024 Financial Results ENGLEWOOD, Colo., October 24, 2024 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2 |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| October 24, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| July 25, 2024 |
Zynex Reports Second Quarter 2024 Financial Results Q2 2024 Revenue Increased 11% to $49.9 Million Exhibit 99.1 Zynex Reports Second Quarter 2024 Financial Results Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational result |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| April 30, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 30, 2024 |
Zynex Reports First Quarter 2024 Financial Results Q1 2024 Revenue Increased 10% to $46.5 Million Exhibit 99.1 Zynex Reports First Quarter 2024 Financial Results Q1 2024 Revenue Increased 10% to $46.5 Million ENGLEWOOD, Colo., April 30, 2024 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational result |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX, |
|
| March 12, 2024 |
ZYNEX, INC. CLAWBACK POLICY EFFECTIVE November 28, 2023 1. Purpose. The purpose of this Zynex Inc. (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comply with, and shall be interpreted to be c |
|
| March 12, 2024 |
Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. Name Jurisdiction Zynex Medical, Inc. Colorado Zynex Monitoring Solutions, Inc. Colorado Zynex NeuroDiagnostics, Inc. Colorado Zynex Europe, ApS Denmark Kestrel Labs, Inc. Colorado |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| February 29, 2024 |
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results FY 2023 Revenue Increased 17% to $184. |
|
| November 1, 2023 |
Zynex Announces Share Repurchase Program Exhibit 99.1 Zynex Announces Share Repurchase Program ENGLEWOOD, CO – November 1, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to repurchase up to $20.0 million of the Comp |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 31, 2023 |
Zynex Announces Review of Strategic Alternatives Exhibit 99.1 Zynex Announces Review of Strategic Alternatives ENGLEWOOD, CO – October 31, 2023 –Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its Board of Directors (the “Board”) has initiated a process to evaluate potential st |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| October 26, 2023 |
Exhibit 99.1 Zynex Reports Third Quarter 2023 Financial Results Q3 2023 Revenue Increased 20% to $49.9 Million; EPS $0.10 ENGLEWOOD, Colo., October 26, 2023 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial and operati |
|
| October 26, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 6, 2023 |
ZYXI / Zynex Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us98986m1036100523.txt us98986m1036100523.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ZYNEX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 98986M103 - (CUSIP Number) September 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| September 11, 2023 |
Zynex Announces Share Repurchase Program Exhibit 99.1 Zynex Announces Share Repurchase Program Englewood, CO – September 11, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to repurchase $10.0 million of the Company' |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Zynex, Inc. (Exact name of registrant as specified in charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E |
|
| July 31, 2023 |
Exhibit 10.1 AMENDMENT TO STOCK PURCHASE AGREEMENT This Amendment, dated and executed effective as of July 27, 2023 (this "Amendment"), to that certain Stock Purchase Agreement, dated as of December 22, 2021 (the "SPA"), entered into by and among Kestrel Labs, Inc., a Colorado corporation (the "Company"), Jonas Pologe, Theodore Delianides, Kurt Aronow and Kevin Galligan (collectively, the "Selling |
|
| July 27, 2023 |
Exhibit 99.1 Zynex Reports Second Quarter 2023 Financial Results Q2 2023 Revenue increased 22% to $45.0 Million; EPS $0.09 ENGLEWOOD, Colo., July 27, 2023 /PRNewswire/ - Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial |
|
| July 27, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 12, 2023 |
Zynex Reports Preliminary Second Quarter 2023 Results Exhibit 99.1 Zynex Reports Preliminary Second Quarter 2023 Results ENGLEWOOD, CO – July 12, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for second quarter 2023 and reiterated full-year guidance. "Zy |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| June 20, 2023 |
Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management Exhibit 99.1 Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management Englewood, CO – June 20, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the FDA (Food and Drug Administration) has |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| June 14, 2023 |
Zynex Announces Share Buyback Program Exhibit 99.1 Zynex Announces Share Buyback Program Englewood, CO – June 14, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common s |
|
| May 24, 2023 |
ZYXI / Zynex Inc / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 17) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9655 Maroon Circle Englewood, CO |
|
| May 24, 2023 |
AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Exhibit 99.1 AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of ZYNEX, INC., a Nevada co |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| May 9, 2023 |
Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes Exhibit 99.1 Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes ENGLEWOOD, Colo., May 3, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), today announced its intent to offer, subject to market conditions and other factors, $50 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes") in a private offering (the "Notes Offering") to per |
|
| May 9, 2023 |
Zynex Announces Update Regarding Previously Announced Offerings Exhibit 99.4 Zynex Announces Update Regarding Previously Announced Offerings ENGLEWOOD, Colo., May 4, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), today announced that Thomas Sandgaard, its Chief Executive Officer (the "Selling Stockholder"), has determined not to pursue the public offering of 2,000,000 shares of the Company's common stock that was previously announced on May 3, 2023 |
|
| May 9, 2023 |
Exhibit 4.1 ZYNEX, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 9, 2023 5.00% Convertible Senior Notes due 2026 TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designation and Amount 14 Section 2.0 |
|
| May 9, 2023 |
Zynex Announces Proposed Secondary Public Offering of Common Stock Exhibit 99.3 Zynex Announces Proposed Secondary Public Offering of Common Stock ENGLEWOOD, Colo., May 3, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex" or "the Company") (Nasdaq: ZYXI), today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock by Thomas Sandgaard, its Chief Executive Officer (the "Secondary Offering"). Mr. Sandgaard also intends to grant |
|
| May 9, 2023 |
Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering Exhibit 99.2 Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering ENGLEWOOD, Colo., May 4, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI ), announced today the pricing of its previously announced private offering of $52.5 million aggregate principal amount of 5.00% convertible senior notes due 2026 (the "Notes") in a private offering (the "Notes Offering") to persons reas |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.S |
|
| May 9, 2023 |
Exhibit 4.2 EXHIBIT A [FORM OF FACE OF NOTE] [INCLUDE FOLLOWING LEGEND IF A GLOBAL NOTE] [UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME A |
|
| May 3, 2023 |
SUBJECT TO COMPLETION, DATED MAY 3, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 27, 2023 |
Zynex Announces 2023 First Quarter Earnings Exhibit 99.1 Zynex Announces 2023 First Quarter Earnings Englewood, CO, April 27, 2023 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights: o |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 11, 2023 |
Zynex Reports Preliminary First Quarter 2023 Results Exhibit 99.1 Zynex Reports Preliminary First Quarter 2023 Results ENGLEWOOD, CO – April 11, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for first quarter 2023 and reiterated full year guidance. "We |
|
| March 30, 2023 |
DEF 14A 1 tm2310595d1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX, |
|
| March 14, 2023 |
Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. Name Jurisdiction Zynex Medical, Inc. Colorado Zynex Monitoring Solutions, Inc. Colorado Zynex NeuroDiagnostics, Inc. Colorado Zynex Europe, ApS Denmark Kestrel Labs, Inc. Colorado |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| March 13, 2023 |
Zynex Announces 2022 Fourth Quarter and Full Year Earnings Exhibit 99.1 Zynex Announces 2022 Fourth Quarter and Full Year Earnings Englewood, CO, March 13, 2023 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 2022. |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| February 21, 2023 |
Zynex Leases New Facility to Accommodate Growth Exhibit 99.1 Zynex Leases New Facility to Accommodate Growth ENGLEWOOD, Colo., February 21, 2023 /PRNewswire/ - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the lease of a new 41,000 square foot facility to accommodate Zynex M |
|
| February 1, 2023 |
ZYXI / Zynex Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us98986m1036020123.txt us98986m1036020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) ZYNEX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 98986M103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 1, 2022 |
Zynex Announces Additional Share Buyback Program Exhibit 99.1 Zynex Announces Additional Share Buyback Program Englewood, CO – November 1, 2022 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Comp |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 27, 2022 |
Zynex Announces 2022 Third Quarter Earnings Exhibit 99.1 Zynex Announces 2022 Third Quarter Earnings Englewood, CO, October 27, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlig |
|
| October 27, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 28, 2022 |
Zynex Announces 2022 Second Quarter Earnings Exhibit 99.1 Zynex Announces 2022 Second Quarter Earnings Englewood, CO, July 28, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights: |
|
| July 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 11, 2022 |
Exhibit 99.1 Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance ENGLEWOOD, CO ? July 11, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for secon |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| June 13, 2022 |
Letter from Plante & Moran PLLC Exhibit 16.1 Plante & Moran, PLLC Suite 600 8181 E. Tufts Avenue Denver, CO 80237 Tel: 303.740.9400 Fax: 303.740.9009 plantemoran.com June 13, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read Item 4.01 included in the Form 8-K of Zynex, Inc. filed with the Securities and Exchange Commission regarding its change in auditors. We agree with t |
|
| June 13, 2022 |
Zynex Announces Change of Auditor Exhibit 99.1 Zynex Announces Change of Auditor Englewood, CO ? June 13, 2022 ? Zynex, Inc. (?Zynex or the ?Company) (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC (?Plante Moran?) a |
|
| June 13, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| June 9, 2022 |
Zynex Announces Additional Share Buyback Program Exhibit 99.1 Zynex Announces Additional Share Buyback Program Englewood, CO ? June 9, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company' |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| April 29, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 29, 2022 |
Zynex Announces 2022 First Quarter Earnings Exhibit 99.1 Zynex Announces 2022 First Quarter Earnings Englewood, CO, April 28, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the first quarter ended March 31, 2022. Highlights: o Revenue increased |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 11, 2022 |
Zynex Announces Share Buyback Program Exhibit 99.1 Zynex Announces Share Buyback Program ENGLEWOOD, CO ? April 11, 2022 ? Zynex, Inc. (NASDAQ: ZYXI an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common sto |
|
| April 8, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| April 8, 2022 |
Zynex Reports Preliminary First Quarter 2022 Results and Provides Business Update Exhibit 99.1 Zynex Reports Preliminary First Quarter 2022 Results and Provides Business Update ENGLEWOOD, CO ? April 8, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for first quarter 2022, affirming |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 22, 2022 |
Exhibit 21 ? SUBSIDIARIES OF ZYNEX, INC. ? ? ? ? Name Jurisdiction Zynex Medical, Inc. ? Colorado Zynex Monitoring Solutions, Inc. ? Colorado Zynex NeuroDiagnostics, Inc. ? Colorado Zynex Europe, ApS ? Denmark Pharmazy, Inc ? Colorado Kestrel Labs, Inc. ? Colorado ? |
|
| March 22, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zynex Inc. (?Zynex? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). DESCRIPTION OF COMMON STOCK The authorized capital stock of the Company consists of 100,000,000 shares of |
|
| February 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| February 28, 2022 |
Zynex Announces 2021 Fourth Quarter and Full Year Earnings Exhibit 99.1 Zynex Announces 2021 Fourth Quarter and Full Year Earnings Englewood, CO, February 24, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 20 |
|
| February 7, 2022 |
ZYXI / Zynex Inc. / BlackRock Inc. Passive Investment us98986m1036020722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ZYNEX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 98986M103 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 18, 2022 |
Zynex Announces Increased Q4 2021 Adjusted EBITDA Estimate and 18% Order Growth Exhibit 99.1 Zynex Announces Increased Q4 2021 Adjusted EBITDA Estimate and 18% Order Growth ENGLEWOOD, CO ? January 18, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today announced order growth and an increased Adjusted EBITDA estimate |
|
| January 18, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 (December 22, 2021) ZYNEX, INC. (Exact name of registrant as specified in charter) Nevada 001-38804 90-0275169 (State or other jurisdiction (Commission (IRS Employer |
|
| December 30, 2021 |
Exhibit 10.1 loan AGREEMENT This Agreement dated as of December 22, 2021 is among Bank of America, N.A. (the "Bank") and Zynex Medical, Inc. and Zynex Monitoring Solutions, Inc. (collectively, jointly and severally, the "Borrower"). 1. definitions In addition to the terms which are defined elsewhere in this Agreement, the following terms have the meanings indicated for the purposes of this Agreeme |
|
| December 23, 2021 |
Zynex Announces Acquisition of Kestrel Labs Expanding Its Product Portfolio in Patient Monitoring EXHIBIT 99.1 Zynex Announces Acquisition of Kestrel Labs Expanding Its Product Portfolio in Patient Monitoring ENGLEWOOD, CO ? December 23, 2021 / PRNewswire/ - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has acquired 100% |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 (December 22, 2021) ZYNEX, INC. (Exact name of registrant as specified in charter) Nevada 001-38804 90-0275169 (State or other jurisdiction (Commission (IRS Employer |
|
| December 23, 2021 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT by and among Kestrel Labs, Inc., Zynex Monitoring Solutions Inc., Zynex, Inc. and the Selling Shareholders named herein dated as of December 22, 2021 TABLE OF CONTENTS ARTICLE I DEFINITIONS 2 ARTICLE II PURCHASE AND SALE 16 Section 2.01 Purchase and Sale. 16 Section 2.02 Purchase Price. 16 Section 2.03 Transactions to be Effected at the Closing. 16 Section 2.0 |
|
| November 10, 2021 |
Zynex Declares Special Cash Dividend of $0.10 Per Share and 10% Stock Dividend Exhibit 99.1 Zynex Declares Special Cash Dividend of $0.10 Per Share and 10% Stock Dividend ENGLEWOOD, CO ? November 10, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced it has declared a one |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 2, 2021 |
Zynex Announces 2021 Third Quarter Earnings Exhibit 99.1 Zynex Announces 2021 Third Quarter Earnings ? 2021 Third Quarter o Revenue increased 74% year over year to $34.8 million o Orders increased 70% o Record net income of $6.1 million; Diluted EPS $0.17 o Adjusted EBITDA $9.3 million ENGLEWOOD, CO ? November 2, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invas |
|
| November 2, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 13, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 13, 2021 |
Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate Exhibit 99.1 Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate ENGLEWOOD, CO ? October 13, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 29, 2021 |
Zynex Announces 2021 Second Quarter Earnings Exhibit 99.1 Zynex Announces 2021 Second Quarter Earnings ? 2021 Second Quarter o Revenue increased 61% year over year to $31.0 million o Orders increased 247% o Net income of $2.8 million; Diluted EPS $0.08 o Adjusted EBITDA $4.8 million ENGLEWOOD, CO ? July 29, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive med |
|
| July 15, 2021 |
Zynex Announces 247% Order Growth and Increases Q2 Adjusted EBITDA Estimate Exhibit 99.1 Zynex Announces 247% Order Growth and Increases Q2 Adjusted EBITDA Estimate ENGLEWOOD, CO ? July 15, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjust |
|
| July 15, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R. |
|
| April 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 29, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 29, 2021 |
Zynex Announces 2021 First Quarter Earnings Exhibit 99.1 Zynex Announces 2021 First Quarter Earnings ? 2021 First Quarter o Revenue increased 58% year over year to $24.1 million o Orders increased 140% o Net loss of $0.7 million; GAAP loss per share $0.02 o Adjusted EBITDA loss $0.4 million ENGLEWOOD, CO ? April 29, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-in |
|
| April 12, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I. |
|
| April 12, 2021 |
Zynex Announces 140% Year over Year Order Growth in Q1-2021 Exhibit 99.1 Zynex Announces 140% Year over Year Order Growth in Q1-2021 ENGLEWOOD, CO – April 12, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q1 2021. Thomas Sandgaard, CEO of |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| April 9, 2021 |
Exhibit 10.1 SUBLEASE AGREEMENT This Sublease Agreement (?Sublease?) is dated April 8, 2021, and is between COGNIZANT TRIZETTO SOFTWARE GROUP, INC., a Delaware corporation (?Sublandlord?), and ZYNEX, INC., a Nevada corporation (?Subtenant?). Sublandlord, by its predecessor in interest, The Trizetto Group, Inc., as tenant, and Maroon Englewood LLC, a Delaware limited liability company (?Prime Landl |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 8, 2021 |
Zynex Announces Share Buyback Program Exhibit 99.1 Zynex Announces Share Buyback Program ENGLEWOOD, CO – March 8, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back $10.0 m |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| February 25, 2021 |
Table of Contents ? ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2021 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zynex Inc. (?Zynex? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). DESCRIPTION OF COMMON STOCK The authorized capital stock of the Company consists of 100,000,000 shares of |
|
| February 25, 2021 |
Zynex Announces 2020 Fourth Quarter and Full Year Earnings Exhibit 99.1 Zynex Announces 2020 Fourth Quarter and Full Year Earnings · 2020 Full Year o Revenue increased 76% year over year to $80.1 million o Orders increased 96% o Net income of $9.1 million; Diluted EPS $0.26 o Adjusted EBITDA $13.7 million o 2020 Revenue and Adjusted EBITDA are the highest in Company history · 2020 Fourth Quarter o Revenue increased 81% year over year to $25.6 million o Or |
|
| February 25, 2021 |
Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. ? ? ? ? ? Name Jurisdiction Zynex Medical, Inc. ? Colorado ? Zynex Monitoring Solutions, Inc. ? Colorado ? Zynex NeuroDiagnostics, Inc. ? Colorado ? Zynex Europe, ApS ? Denmark ? Pharmazy, Inc ? Colorado ? ? |
|
| February 25, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| February 2, 2021 |
us98986m1036020221.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ZYNEX INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 98986M103 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 28, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into effective January 27, 2021 (the “Effective Date”), by Anna Lucsok (“Executive”) and Zynex Medical (the “Company”). RECITALS A. Company desires to hire Executive as Chief Operating Officer and to compensate Executive for Executive’s services to the Company; and B. Executive wishes to be employed by the Co |
|
| January 28, 2021 |
Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical Exhibit 99.1 Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical ENGLEWOOD, Colo., (PR Newswire, January 28, 2021) - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has pr |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| January 12, 2021 |
Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| January 12, 2021 |
Zynex Announces 117% Year over Year Order Growth and Increases Adjusted EBITDA Estimate Exhibit 99.1 Zynex Announces 117% Year over Year Order Growth and Increases Adjusted EBITDA Estimate ENGLEWOOD, CO – January 12, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q4 2 |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| December 2, 2020 |
ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 16) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO |
|
| December 2, 2020 |
AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Exhibit 99.1 AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of ZYNEX, INC., a Nevada co |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 27, 2020 |
Zynex Announces Third Quarter 2020 Earnings Exhibit 99.1 Zynex Announces Third Quarter 2020 Earnings · Revenue increased 69% year over year to $20.0 million · Orders increased 96% · Net income of $1.3 million; Diluted EPS $0.04 · Adjusted EBITDA $2.4 million ENGLEWOOD, CO – October 27, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain |
|
| October 27, 2020 |
Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 27, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| October 23, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into effective October 5th, 2020 (the “Effective Date”), by Neil Friery (“Executive”) and Zynex, Inc. (the “Company”). RECITALS A. Company desires to hire Executive as President and Chief Operating Officer and to compensate Executive for Executive’s services to the Company; and B. Executive wishes to be emplo |
|
| October 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 23, 2020 |
Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division Exhibit 99.1 Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division ENGLEWOOD, Colo., (PR Newswire, October 23, 2020) - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics |
|
| October 13, 2020 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number ( |
|
| October 13, 2020 |
Zynex Announces 96% Year over Year Order Growth Exhibit 99.1 Zynex Announces 96% Year over Year Order Growth ENGLEWOOD, CO – October 12, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q3 2020. Thomas Sandgaard, CEO of Zynex said |
|
| October 6, 2020 |
Exhibit 10.1 LEASE AGREEMENT between GIG CW COMPARK, LLC (“Landlord”) and ZYNEX, INC. (“Tenant”) Table of Contents Page 1. CERTAIN DEFINED TERMS 1 2. GRANT OF LEASE 2 3. RENT; SECURITY DEPOSIT 3 4. USE 5 5. TAXES 6 6. LANDLORD’S REPAIRS AND OBLIGATIONS 7 7. TENANT’S REPAIRS AND OBLIGATIONS 8 8. ALTERATIONS 9 9. SIGNAGE 10 10. INSPECTION AND RIGHT OF ENTRY 10 11. UTILITIES 10 12. ASSIGNMENT AND SUB |
|
| October 6, 2020 |
Zynex Continued Growth Leads to a New Manufacturing and Warehouse Facility Exhibit 99.1 Zynex Continued Growth Leads to a New Manufacturing and Warehouse Facility ENGLEWOOD, CO – October 6, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the lease of a new 50,488 squ |
|
| October 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| September 10, 2020 |
Zynex Reaches 400 Salesperson Milestone Ahead of Schedule Exhibit 99.1 Zynex Reaches 400 Salesperson Milestone Ahead of Schedule ENGLEWOOD, CO – September 10, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced reaching four hundred sales reps in the U.S |
|
| September 10, 2020 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| September 9, 2020 |
Zynex reports 83% Order Growth for July and August Exhibit 99.1 Zynex reports 83% Order Growth for July and August ENGLEWOOD, CO – September 3, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced order growth for July and August 2020. Aggregate or |
|
| September 9, 2020 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number |
|
| July 28, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 28, 2020 |
Zynex Announces Second Quarter 2020 Earnings Exhibit 99.1 Zynex Announces Second Quarter 2020 Earnings · Revenue increased 87% year over year to $19.3 million · Orders increased 37% · Net income of $3.0 million; Diluted EPS $0.09 · Adjusted EBITDA increased 69% to $4.8 million ENGLEWOOD, CO – July 28, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical d |
|
| July 28, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| July 20, 2020 |
ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 15) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO |
|
| July 17, 2020 |
Exhibit 1.1 Execution Version 2,500,000 Shares1 ZYNEX, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT July 14, 2020 PIPER SANDLER & CO. As Representative of the several Underwriters named in Schedule II hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Zynex, Inc., a Nevada corporation (the “Company”), and |
|
| July 17, 2020 |
Zynex, Inc. Prices Public Offering of Common Stock Exhibit 99.1 Zynex, Inc. Prices Public Offering of Common Stock ENGLEWOOD, Colo., July 14, 2020 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today the pricing of its previously |
|
| July 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R |
|
| July 16, 2020 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-230128 PROSPECTUS SUPPLEMENT (To Prospectus dated March 12, 2019) 1,250,000 Shares ZYNEX, INC. Common Stock $22.00 per share • Zynex, Inc. is offering 1,250,000 shares. • Our common stock is listed on the Nasdaq Capital Market under the symbol “ZYXI.” • The last reported sale price for our common stock on the Nasdaq Capital |
|
| July 16, 2020 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-232367 PROSPECTUS SUPPLEMENT (To Prospectus dated July 3, 2019) 1,250,000 Shares ZYNEX, INC. Common Stock $22.00 per share • The selling stockholders identified in this prospectus supplement are offering an aggregate of 1,250,000 shares of our common stock. We will not receive any of the proceeds from the sale of the shares |
|
| July 14, 2020 |
SUBJECT TO COMPLETION, DATED JULY 14, 2020 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 14, 2020 |
SUBJECT TO COMPLETION, DATED JULY 14, 2020 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 13, 2020 |
Zynex Announces 37% Order Growth and Increases Q2 and Full-Year Revenue Estimates Exhibit 99.1 Zynex Announces 37% Order Growth and Increases Q2 and Full-Year Revenue Estimates ENGLEWOOD, CO – July 9, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased r |
